- NEWS FEATURE
Four key questions on the new wave of anti-obesity drugs

Illustration by Karol Banach
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 620, 28-30 (2023)
doi: https://doi.org/10.1038/d41586-023-02445-4
References
Rubino, D. M. et al. JAMA 327, 138–150 (2022).
Jastreboff, A. M. et al. N. Engl. J. Med. 387, 205–216 (2022).
Borner, T. et al. Diabetes 70, 2545–2553 (2021).
Jastreboff, A. M. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2301972 (2023).
Acosta, A. et al. Obesity 29, 662–671 (2021).
Ferreira, M. C. et al. Diabetol. Metab. Syndr. 11, 10 (2019).
Dawed, A. Y. et al. Lancet Diabetes Endocrinol. 11, 33–41 (2023).
Jall, S. et al. Mol. Metab. 6, 440–446 (2017).
Faillie, J.-L. et al. Clin. Pharm. Therap. 111, 272–282 (2022).
Wilding, J. P. H. et al. N. Engl. J. Med. 384, 989–1002 (2021).
Tomiyama, A., Hunger, J., Nguyen-Cuu, J. & Wells, C. Int. J. Obes. 40, 883–886 (2016).